This application claims the benefit of PCT Patent Application Ser. No. PCT/GB02/05242, filed Nov. 21, 2002 claiming priority to GB 0127888.6 filed on Nov. 21, 2001, titled “A Helical Formation for a Conduit,” which is incorporated by reference in its entirety.
The invention relates to a helical formation for a conduit.
A number of documents have proposed using helical formations in conduits to encourage a desired flow pattern of a fluid within the conduit. Such helical formations have been proposed for a wide variety of applications, including pipelines and blood flow tubing. The purpose of the helical formations is generally to generate spiral flow of the fluid within the conduit to reduce turbulence and dead spots within the conduit.
Although the use of helical formations has been proposed as beneficial to fluid flow in conduits by helping to generate spiral fluid flow patterns, there is little or no information on the physical characteristics of the helical formation that is required to create a suitable spiral flow pattern. Clearly, some designs of helical formations will be ineffective at creating spiral flow and others will not create a beneficial spiral flow. For example, helical formations having a high helix angle may tend to create turbulence rather than spiral flow due.
In accordance with a first aspect of the present invention, there is provided a helical formation for a conduit, the helical formation comprising an elongate member defining at least a portion of a helix, the elongate member comprising two inwardly extending portions, the inwardly extending portions being spaced from each other, extending along the length of the elongate member in side-by-side relationship.
The terms “helical”, “helix” and “spiral” as used herein cover the mathematical definition of helical and any combination of the mathematical definitions of helical and spiral.
Typically, the longitudinally extending member further comprises an intermediate portion that separates the two Inwardly extending portions.
Preferably, the inwardly extending portions extend inwardly of the helix defined by the longitudinally extending member by substantially the same distance. However, it is possible that they could extend inwardly by different distances.
The helical formation may be in the form of an insert adapted to be inserted into the conduit, in use. The insert may be removably inserted or may be permanently inserted.
Alternatively, the helical formation may be an integral part of a side wall of the conduit. For example, the helical formation may be formed by a deformation of a portion of the side wall of the conduit.
In one example of the invention, the helical formation may be for use in blood flow tubing for the human or animal body. The tubing may be synthetic or natural blood flow tubing. For example, the tubing may be a graft. In another example, the conduit may be a stent for insertion into blood flow tubing in the human or animal body.
An example of a helical formation in accordance with the invention will now be described with reference to the accompanying drawings, in which:
A cross-sectional view of the insert 2 is shown in
In use, the stent 1 is inserted into a blood vessel in the human or animal body in a collapsed configuration and after it is located in the correct position, It is expanded to engage with the side walls of the blood vessel to locate the stent 1 in the desired position. Typically, the stent 1 is inserted on a balloon catheter with the stent 1 in the collapsed configuration around the collapsed balloon of the catheter. When the stent 1 is in the correct position in a blood vessel, the balloon is then inflated by pumping fluid into the balloon through the catheter. The expansion of the balloon expands the stent 1 Into engagement with the internal side walls of the blood vessel. The configuration of the stent 1 shown In
When the stent 1 is collapsed onto the balloon of the catheter, the insert 2 is designed such that the fins 6, 7 are bent inwardly so that the fins of the insert collapse so as to reduce the volume occupied by the insert 2 when the stent 1 is in the collapsed configuration. This is illustrated in
After insertion and placement in the desired blood vessel, the insert 2, due to its helical shape, acts on blood flowing through the stent 1 to generate a spiral flow component in the blood.
The length of the stent 1 is to a large extent dictated by enabling sufficient flexibility to ensure that the stent 1 can be inserted into the desired location in the human or animal body. This is normally performed by insertion through the femoral artery. Accordingly, the stent 1 typically has a length in the region of 10 mm to 70 mm and normally approximately 30 mm to 40 mm in length. In order for the insert 2 to generate spiral flow of blood passing through the stent 1, the helix angle of the helix defined by the insert 2 must not be too high. Therefore, to generate an effective spiral flow component, the insert 2 typically defines only a portion of one revolution of the helix that it defines. Preferably, this is at least 50% of one revolution and most preferably greater than 70% of one revolution, but less than one full revolution.
When blood flows through the stent 1, the helical formation of the insert 2 will tend to generate a spiral flow formation in the blood exiting from the stent 1. This spiral flow tends to reduce turbulence and promote better flow of blood within the blood vessels of the human or animal body into which it is inserted.
In contrast,
Therefore, the invention has the advantage that the use of a helical formation having two fins, such as the helical formation 2, promotes better spiral flow patterns of fluid flowing through a conduit.
Although the example described above was in relation to helical formations in stents, helical formations using two fins could also be used in other applications to generate spiral flow of fluid within conduits. For example, the helical formation could be used in a graft for blood vessels, or in any other conduit where it is desired to generate spiral flow of fluid within the conduit.
Number | Date | Country | Kind |
---|---|---|---|
0127888.6 | Nov 2001 | GB | national |
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/GB02/05242 | 11/21/2002 | WO | 00 | 10/29/2004 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO03/045279 | 6/5/2003 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2831662 | Hirsch | Apr 1958 | A |
4161966 | Scheffler et al. | Jul 1979 | A |
4420019 | Dillon | Dec 1983 | A |
4553545 | Maass et al. | Nov 1985 | A |
4760849 | Kropf | Aug 1988 | A |
5416270 | Kanao | May 1995 | A |
5500013 | Buscemi et al. | Mar 1996 | A |
5669420 | Herrero et al. | Sep 1997 | A |
5924456 | Simon | Jul 1999 | A |
6019779 | Thorud et al. | Feb 2000 | A |
6063111 | Hieshima et al. | May 2000 | A |
6156062 | McGuinness | Dec 2000 | A |
6572648 | Klumb et al. | Jun 2003 | B1 |
6645237 | Klumb et al. | Nov 2003 | B2 |
6660032 | Klumb et al. | Dec 2003 | B2 |
6675901 | Johnson et al. | Jan 2004 | B2 |
6776194 | Houston et al. | Aug 2004 | B2 |
6921414 | Klumb et al. | Jul 2005 | B2 |
20010027693 | Blaurock | Oct 2001 | A1 |
20020179166 | Houston et al. | Dec 2002 | A1 |
20040037986 | Houston et al. | Feb 2004 | A1 |
20060124187 | Houston et al. | Jun 2006 | A1 |
Number | Date | Country |
---|---|---|
0 077 130 | Apr 1983 | EP |
2 655 548 | Jun 1991 | FR |
WO 00 38591 | Jul 2000 | WO |
Number | Date | Country | |
---|---|---|---|
20050061380 A1 | Mar 2005 | US |